Reduced antioxidant defense in early onset first-episode psychosis: a case-control study
Open Access
- 14 February 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Psychiatry
- Vol. 11 (1), 26
- https://doi.org/10.1186/1471-244x-11-26
Abstract
Our objective is to determine the activity of the antioxidant defense system at admission in patients with early onset first psychotic episodes compared with a control group. Total antioxidant status (TAS) and lipid peroxidation (LOOH) were determined in plasma. Enzyme activities and total glutathione levels were determined in erythrocytes in 102 children and adolescents with a first psychotic episode and 98 healthy controls. A decrease in antioxidant defense was found in patients, measured as decreased TAS and glutathione levels. Lipid damage (LOOH) and glutathione peroxidase activity was higher in patients than controls. Our study shows a decrease in the antioxidant defense system in early onset first episode psychotic patients. Glutathione deficit seems to be implicated in psychosis, and may be an important indirect biomarker of oxidative stress in early-onset schizophrenia. Oxidative damage is present in these patients, and may contribute to its pathophysiology.This publication has 68 references indexed in Scilit:
- Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)European Psychiatry, 2009
- The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episodeJournal of Affective Disorders, 2008
- Impaired glutathione synthesis in schizophrenia: Convergent genetic and functional evidenceProceedings of the National Academy of Sciences of the United States of America, 2007
- The child and adolescent first-episode psychosis study (CAFEPS): Design and baseline resultsSchizophrenia Research, 2007
- Schizophrenia and Oxidative Stress: Glutamate Cysteine Ligase Modifier as a Susceptibility GeneAmerican Journal of Human Genetics, 2006
- Oxidative stress and neurodegeneration: where are we now?Journal of Neurochemistry, 2006
- Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychoticsSchizophrenia Research, 2006
- Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophreniaInternational Review of Psychiatry, 2006
- Glutathione Pathways in the BrainBiological Chemistry, 2003
- γ‐Glutamylglutamine and Taurine Concentrations Are Decreased in the Cerebrospinal Fluid of Drug‐Naive Patients with Schizophrenic DisordersJournal of Neurochemistry, 1995